Largest biotech by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Gilead Sciences leads the 24 biotech ranked by net assets, at DKK 154.5B, ahead of BioNTech (DKK 145.2B) and Biogen (DKK 124.3B). Figures as of 18 Nov 2026, 14:43 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Gilead SciencesDKK 154.5B
- Median
- DKK 13.7B
- Combined market value
- DKK 5.77T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | DKK 154.5B | DKK 1.43T | DKK 1,154.93 | 0.34% down | 33% up | ||
| 2 | BioNTechBNTX · Health Care | DKK 145.2B | DKK 143.6B | DKK 579.34 | 0.30% up | 16% down | ||
| 3 | BiogenBIIB · Health Care | DKK 124.3B | DKK 253.4B | DKK 1,714.01 | 0.41% up | 49% up | ||
| 4 | AmgenAMGN · Health Care | DKK 58.9B | DKK 1.67T | DKK 3,082.53 | 1.10% down | 34% up | ||
| 5 | ModernaMRNA · Health Care | DKK 58.9B | DKK 571.2B | DKK 1,411.80 | 0.30% up | 755% up | ||
| 6 | argenxARGX · Health Care | DKK 49.8B | DKK 411B | DKK 6,535.53 | 1.34% up | 4% up | ||
| 7 | QiagenQGEN · Health Care | DKK 25.7B | DKK 69.9B | DKK 338.42 | 0.06% down | 12% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | DKK 22.1B | DKK 114.1B | DKK 1,127.16 | 0.19% down | 20% up | ||
| 9 | VaxcytePCVX · Health Care | DKK 18.3B | DKK 63.8B | DKK 403.11 | 0.29% down | 22% up | ||
| 10 | ExelixisEXEL · Health Care | DKK 14.7B | DKK 113.9B | DKK 466.76 | 0.11% up | 63% up | ||
| 11 | Bio-TechneTECH · Health Care | DKK 14.3B | DKK 77.8B | DKK 495.00 | 0.13% up | 26% up | ||
| 12 | RepligenRGEN · Health Care | DKK 14.3B | DKK 74B | DKK 1,157.68 | 4.87% up | 5% up | ||
| 13 | CRISPR TherapeuticsCRSP · Health Care | DKK 13.1B | DKK 27.7B | DKK 285.86 | 4.60% up | 21% down | ||
| 14 | Revolution MedicinesRVMD · Health Care | DKK 11.1B | DKK 237.7B | DKK 1,099.15 | 0.74% down | 131% up | ||
| 15 | Kymera TherapeuticsKYMR · Health Care | DKK 10.8B | DKK 71.3B | DKK 835.63 | 1.03% up | 87% up | ||
| 16 | Krystal BiotechKRYS · Health Care | DKK 8.3B | DKK 61B | DKK 2,058.63 | 1.31% up | 46% up | ||
| 17 | ImmunovantIMVT · Health Care | DKK 5.8B | DKK 47.2B | DKK 228.15 | 0.93% up | 43% up | ||
| 18 | CG OncologyCGON · Health Care | DKK 5.1B | DKK 48.3B | DKK 540.30 | 0.56% up | 85% up | ||
| 19 | Twist BioscienceTWST · Health Care | DKK 3.2B | DKK 52.6B | DKK 771.31 | 1.18% up | 340% up | ||
| 20 | Scholar Rock HoldingSRRK · Health Care | DKK 1.7B | DKK 38.7B | DKK 317.25 | 3.39% up | 14% up | ||
| 21 | Adaptive BiotechnologiesADPT · Health Care | DKK 1.5B | DKK 31.7B | DKK 195.75 | 0.95% up | 88% up | ||
| 22 | Kodiak SciencesKOD · Health Care | DKK 1.1B | DKK 42.9B | DKK 656.28 | 0.39% down | 396% up | ||
| 23 | Halozyme TherapeuticsHALO · Health Care | DKK 332.3M | DKK 74.7B | DKK 654.96 | 0.27% up | 37% up | ||
| 24 | ImmunityBioIBRX · Health Care | -DKK 3.4B | DKK 45B | DKK 42.34 | 0.64% down | 193% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 6.8065 DKK).
Questions and answers
Which biotech rank first by net assets?
Gilead Sciences (DKK 154.5B), BioNTech (DKK 145.2B) and Biogen (DKK 124.3B) are the top three of the 24 biotech ranked by net assets as of 18 Nov 2026, 14:43 UTC.
How many biotech are in this ranking?
24 are ranked by net assets.
What are these biotech worth together?
The 24 biotech ranked by net assets have a combined market value of DKK 5.77T as of 18 Nov 2026, 14:43 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by net assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.